News
BIOL
--
0.00%
--
BIOLASE Announces the Launch of Waterlase Endo Academy
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, completed its leadership council meeting of the Waterlase Endo Academy on Nov. 14, forming an exclusive community of leading endodontists, dedicated to improving patient outcomes and profitability with new technology. The academy, open to all Waterlase endodontists, was created to foster peer-led learning, best practice sharing and optimal integration of Waterlase technology into clinical practice.
PR Newswire · 11/17 14:00
BIOLASE, Inc. (NASDAQ:BIOL) Just Reported Earnings, And Analysts Cut Their Target Price
It's been a good week for BIOLASE, Inc. (NASDAQ:BIOL) shareholders, because the company has just released its latest...
Simply Wall St. · 11/15 12:27
Biolase EPS misses by $0.16, beats on revenue
Biolase (BIOL): Q3 GAAP EPS of -$0.21 misses by $0.16.Revenue of $6.54M (-24.4% Y/Y) beats by $0.04M.Press Release
Seekingalpha · 11/12 21:10
BIOLASE Reports Strong Sequential Revenue Growth In Third Quarter 2020
PR Newswire · 11/12 21:05
BIOLASE, Inc. to Host Earnings Call
ACCESSWIRE · 11/12 19:30
Preview: Biolase's Earnings
On Thursday, November 12, Biolase (NASDAQ: BIOL) will report its last quarter's earnings. Here is Benzinga's preview of the company's release.What Are Earnings, Net Income, And Earnings Per Share? Earnings and especially earnings per share (EPS) are useful measures of a company's profitability. Total earnings, which is also referred to as net income, equals total revenue minus total expenses. EPS equals to net income divided by the number of shares outstanding.Earnings And Revenue Sell-side analysts are expecting Biolase's loss per share to be near $0.05 on sales of $6.50 million. Biolase EPS in the same period a year ago totaled $0.25. Sales were $8.65 million.Why Analyst Estimates And Earnings Surprises Are Important Wall Street analysts who study this company will publish analyst estimates of revenue and EPS. The averages of all analyst EPS and revenue estimates are called the "consensus estimates"; these consensus estimates can have a significant effect on a company's performance during an earnings release. When a company posts earnings or revenue above or below a consensus estimate, it has posted an "earnings surprise", which can really move a stock depending on the difference between actual and estimated values.View more earnings on BIOLIf the company were to post earnings in line with the consensus estimate when it reports Thursday, EPS would be up 80.0%. Sales would be down 24.82% from the year-ago period. In comparison to analyst estimates in the past, here is how the company's reported EPS stacks up:Quarter Q2 2020 Q1 2020 Q4 2020 Q3 2019 EPS Estimate -0.17 -0.14 -0.05 -0.13 EPS Actual -0.12 -0.19 -0.13 -0.25 Revenue Estimate 2.09 M 4.98 M 13.33 M 9.66 M Revenue Actual 2.94 M 4.78 M 10.18 M 8.65 M Stock Performance Shares of Biolase were trading at $0.3036 as of November 10. Over the last 52-week period, shares are down 42.18%. Given that these returns are generally negative, long-term shareholders are probably a little upset going into this earnings release.Do not be surprised to see the stock move on comments made during its conference call. Biolase is scheduled to hold the call at 16:30:00 ET and can be accessed here.See more from Benzinga * Click here for options trades from Benzinga * Farfetch's Earnings: A Preview * Lantronix's Earnings: A Preview(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga · 11/11 15:13
BIOLASE, Inc. to Report Third Quarter 2020 Results on November 12, 2020
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced that it will release third quarter 2020 financial and operating results on Thursday, November 12, 2020 after the close of the U.S. financial markets and will host a conference call and webcast that day at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results and corporate developments.
PR Newswire · 11/05 12:30
BIOLASE Announces Launch On M-Vest
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced that it has made available an updated corporate presentation and business summary overview on M-Vest.com. The Company plans to provide regular updates through this website. Please visit www.m-vest.com/insights/spotlight/biolase-inc to access the M-Vest website and www.biolase.com for more information regarding BIOLASE.
PR Newswire · 10/27 13:30
Why Biolase's Stock Is Trading Higher Today
Biolase (NASDAQ: BIOL) shares are trading higher on Wednesday after the company issued third-quarter sales guidance above analyst estimates.
Benzinga · 10/14 14:24
BIOLASE Announces Preliminary Third Quarter Revenue Results; Reopening Of Dental Practices Drives Sequential Revenue Growth
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced unaudited preliminary revenue results for the third quarter ended September 30, 2020. The Company expects to report third quarter revenue in the range of $6.4 million to $6.6 million, a significant sequential improvement from the 2020 second quarter. Additionally, the Company's U.S. revenue is anticipated to be in-line with its third quarter 2019 U.S. results (pre-COVID-19), as dentists continued to resume normal business practices, while Waterlase sales to new customers accounted for more than 90% of the Company's total U.S. laser revenue during the third quarter of 2020.
PR Newswire · 10/14 12:30
Here's Why You Should Hold on to Stryker (SYK) Stock Now
Stryker (SYK) continues to benefit from strength in its robotic-arm assisted surgery platform - Mako and broad product portfolio. However, pricing pressure raises concern.
Zacks · 10/13 09:42
Ecolab Introduces New Automated Precision Dispensing System
Ecolab's (ECL) newly launched Precision Dispensing System for Membranes can drive productivity and boost worker safety.
Zacks · 10/09 11:36
Masimo Unveils New Wearable Wireless Continuous Thermometer
Masimo's (MASI) wearable wireless continuous thermometer offers consumers hassle-free continuous body temperature measurements, thereby eliminating the need for manual measurements.
Zacks · 10/08 15:17
Here's Why You Should Retain Fresenius Medical Stock Now
Fresenius Medical (FMS) continues to gain traction from its broad range of dialysis products and services. However, intense competition remains a woe.
Zacks · 10/06 14:14
BD Gets 510(k) Clearance for Its FACSLyric Flow Cytometer
BD (BDX) gets 510(k) clearance from the FDA for its new integrated system that helps clinical laboratories to fully automate the sample to answer process and boost their efficiency.
Zacks · 10/06 14:12
Biolase Granted European Patent Titled 'HANDPIECE FINGER SWITCH FOR ACTUATION OF HANDHELD MEDICAL INSTRUMENTATION'
https://data.epo.org/publication-server/pdf-document?pn=2521506&ki=B1&cc=EP
Benzinga · 09/23 20:13
BIOLASE Hosts Nearly 400 Dental Professionals During Webinar On Landmark Study On Lasers And Managing Periodontitis
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced that it hosted nearly 400 dental professionals last Thursday evening during a panel discussion on the NEW Journal of Periodontology landmark study from the McGuire Institute comparing periodontal flap surgery to BIOLASE
PR Newswire · 09/15 13:30
BIOLASE Regains Nasdaq Compliance For Minimum Stockholder Equity
PR Newswire · 08/18 11:30
BIOLASE Regains Nasdaq Compliance For Minimum Stockholder Equity
FOOTHILL RANCH, Calif., Aug. 18, 2020 /PRNewswire/ -- BIOLASE, Inc.(NASDAQ:BIOL), the global leader in dental lasers, announced today that it received notification from the Listing Qualifications
Benzinga · 08/18 10:39
Biolase Q2 EPS $(0.08) Beats $(0.17) Estimate, Sales $2.90M Beat $2.09M Estimate
Biolase (NASDAQ:BIOL) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.17) by 52.94 percent. This is a 38.46 percent increase over losses of $(0.13) per share from the same
Benzinga · 08/13 20:14
Webull provides a variety of real-time BIOL stock news. You can receive the latest news about BIOLASE through multiple platforms. This information may help you make smarter investment decisions.
About BIOL
BIOLASE, Inc. (BIOLASE) is a medical device company that develops, manufactures, markets and sells laser systems in dentistry and medicine. The Company markets, sells, and distributes dental imaging equipment, including cone beam digital x-rays and computer-aided design (CAD)/computer-aided manufacturing (CAM) intra-oral scanners, in-office, chair-side milling machines and three-dimensional (3-D) printers. It offers two categories of laser system products: WaterLase (all-tissue) systems and Diode (soft tissue) systems. Its brand, WaterLase, uses a combination of water and laser energy to perform procedures performed using drills, scalpels, and other traditional dental instruments for cutting soft and hard tissue. It also offers its Diode laser systems to perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. Its Waterlase and Diode systems use disposable laser tips of differing sizes and shapes depending on the procedures being performed.
More